CDKN2A and cancer: Patients with discordant HPV and p16 status presented an intermediate survival, with 63.3% 5-year OS and 74.1% 5-year DFS in those with HPVDNA−/p16+ TSCC/BOTSCC, while corresponding figures for those with HPVDNA+/p16− cancers were 57.1% and 85.4% for OS and DFS, respectively.